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 MATERNAL IMMUNE ACTIVATION AND PREECLAMPSIA 
IDA AZIZKHANIAN 
 
ABSTRACT 
  
Schizophrenia and autism are debilitating illnesses thought to have developmental 
etiologies. Prenatal brain damage can alter brain development and cognition leading to 
the pathologies of both diseases. Furthermore, prenatal infections have been implicated as 
a risk factor for both schizophrenia and autism in large, population-based studies. Many 
studies have investigated the effects of prenatal infections on brain development and have 
established inflammatory cytokines as the most likely mediators of brain damage. While 
preeclampsia exposes a fetus to a similar inflammatory environment as a prenatal 
infection, a comprehensive review of the work connecting obstetric complications to 
autism and schizophrenia has not been conducted. The mechanisms explaining the 
induction of altered brain function after fetal neuroinflammation also requires further 
study in the specific context of preeclampsia, especially in regards to what factors may 
differentiate autism from schizophrenia in the course of disease development. 
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INTRODUCTION 	  
Exposure to an inflammatory response in utero has ben implicated as a possible 
risk factor for schizophrenia and autism (ASD) (Meyer, Feldon, & Dammann, 2011). 
Acute neuroinflammation during fetal development may be responsible for some of the 
shared characteristics of these two disorders (Bilbo & Schwarz, 2009). Schizophrenia and 
ASD are characterized by deficits in cognition, sensorimotor gating, emotional 
processing, and executive function to varying degrees as well as structural abnormalities 
in the insular cortex, cerebellum, and fusiform gyrus (Cheung et al., 2010; Rapin & 
Tuchman, 2008). Additionally, both groups display reduced brain activity in the 
prefrontal cortex, amygdala, and fusiform gyrus during social cognition tasks (Pinkham, 
Hopfinger, Pelphrey, Piven, & Penn, 2008).  Further examples of the shared and specific 
pathologies of these diseases are outlined in Table 1. The nature and extent of symptoms 
may vary due to the timing and severity of exposure to inflammation.  
Preeclampsia is associated with an inflammatory response similar to that launched 
by an infection. While many studies have implicated maternal infections in the etiology 
of both disorders, a comprehensive and dedicated review of the impact of preeclampsia 
has not been conducted, nor is there an established mechanism by which inflammation 
could give rise to the pathologies associated with these disorders.  
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Table 1. Autism and Schizophrenia: Related but Opposite Diseases 
Autism	   Both	   Schizophrenia	  Repetitive	  behavior	   Social	  withdrawal	   Paranoia	  Symptoms	  begin	  early	  in	  life	   Communication	  impairment	   Symptoms	  generally	  begin	  in	  early	  adulthood	  Increased	  gray	  and	  white	  matter	   Poor	  eye	  contact~negative	  symptoms	  of	  schizophrenia	   Reduced	  grey	  and	  white	  matter	  Smaller	  corpus	  callosum	   	   Larger	  corpus	  callosum	  Larger,	  more	  dense	  amygdala	   	   Smaller	  amygdala,	  less	  reactive	  High	  BDNF	   	   Low	  BDNF	  
 
While autism and schizophrenia are characterized by shared abnormalities, the diseases 
are often opposite in pathology. Both diseases are associated with abnormal corpus 
callosum density, however schizophrenics tend to have hyperdevelopment in this area 
while autistics are hypertrophied. The fact that that there is an overlap in the pathways 
altered in both diseases suggests they may have common etiology and genetic or 
environmental factors result in different outcomes for how these pathways are altered 
(Crespi & Badcock, 2008). 
 
Schizophrenia is a devastating psychological disorder that affects between 0.5 to 
1% of the world population (“CDC - Burden of Mental Illness - Mental Illness - Mental 
Health Basics - Mental Health,” n.d.). In most cases, the disease is diagnosed before the 
age of thirty, typically 21 years of age for men and 27 years for women. In addition to the 
emotional cost, Schizophrenia was estimated to cost 2.02 billion Canadian dollars in 2004 
due to medical and non-medical cost, and an additional 4.83 billion Canadian dollars due 
to morbidity, unemployment, and loss of productivity. An American study conducted in 
2002 estimated the cost of schizophrenia to be $62 billion in the United States with half 
of that cost being indirect costs not related to healthcare (Wu et al., 2005).  Despite 
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drastic differences in healthcare systems between these two countries, the cost of 
schizophrenia is roughly equal in both countries when adjusting for population. The 
highest economic impact of schizophrenia is associated with onset of the disease, or 
within one year of the first episode of illness (“CDC - Burden of Mental Illness - Mental 
Illness - Mental Health Basics - Mental Health,” n.d.). Therefore, a better understanding 
of risk factors for schizophrenia and monitoring those who are at high risk until past the 
age of 30 may reduce the financial and social cost as well as the outcome of the disease.  
Autism is characterized by severely impaired communication and social 
interaction in addition to repetitive behaviors (Rapin & Tuchman, 2008). ASD occurs in 
1% of the population, however the prevalence may be increasing to either environmental 
factors or increased awareness of the disease leading to changes in diagnostic practices 
(Fombonne, 2009). Prior to the DSM-V, PDD-NOS, Asperger’s, autistic disorder, and 
childhood disintegrative disorder were separately defined. These disorders are now 
collectively referred to as “autism spectrum disorders” (ASD) in the DSM-V. Diagnosis 
of ASD is generally made early in life when developmental milestones are not met. 
Deficits in communication are apparent as early as six months.   
 
Environment, Immunity and Mental Illness  
A prominent hypothesis for the etiology of Schizophrenia suggests that a 
congenital predisposition primes certain individuals for susceptibility to the disease after 
environmental stressors in adolescence (Feigenson, Kusnecov, & Silverstein, 2014). This 
“two hit hypothesis” accounts for the late onset of initial symptoms and the variability in 
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outcomes for those with genetic markers of schizophrenia. In reviews of a large body of 
studies, Feigenson et al (2013) and Khandaker et al (2013) provide evidence that a “first 
hit” can be provided not only by genetic traits, but also harmful prenatal environmental 
exposures such as maternal infection during pregnancy (Feigenson et al., 2014; Golam 
M. Khandaker, Zammit, Lewis, & Jones, 2014). 
 The same immunological insult that can prime a brain for schizophrenia can also 
cause changes in development that manifest as autism, instead. Several studies have 
investigated behavioral deficits reminiscent of autism in mice exposed to inflammation in 
utero (Hsiao & Patterson, 2011). Such mice exhibit increased grooming behavior, deficits 
in social interaction, and exploratory behavior as symptoms of behavioral abnormalities 
that correlate with autism in humans. Furthermore, the differences in timing and severity 
of prenatal neuroinflammation may be responsible for the different pathologies seen in 
schizophrenia and autism despite their possibly shared etiology.  
 
Preeclampsia Immunology   
There is currently lack evidence showing the causal relationship between the 
exposure to preeclampsia during fetal development and incidence of schizophrenia and 
ASD. Preeclampsia is a multifactor disease in which a developing fetus can be exposed to 
a number of environmental stressors, including inflammatory cytokines. Preeclampsia is 
a hypertensive disorder that occurs in 5-8% of pregnancies. It is defined by either a 
systolic blood pressure of >140 or a diastolic pressure of >90 mmHg in addition to 
proteinuria. The cause of preeclampsia is unknown but is suspected to be involved with 
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immune activation in some cases. The maternal immune system can recognize an 
allogenic fetus or be ignited by cell damage due to placental hypoxia (Conrad & Benyo, 
1997; Pennington, Schlitt, Jackson, Schulz, & Schust, 2012). In the latter case, it is also 
possible that placental hypoxia and damage is secondary to hypertension. 
In a systematic review with meta-analysis of several publications, Lau et al found 
that preeclampsia is associated with elevated maternal circulating levels of pro-
inflammatory cytokines such as Il-6 and TNF-α (Lau et al., 2013). Paradoxically, the 
same study found elevated anti-inflammatory Il-10 in maternal circulation. Additionally, 
inflammatory cytokines such as TNF-α are not only found in maternal circulation during 
preeclampsia but are also found at elevated levels in amniotic fluid, directly exposing the 
fetus to these factors (Kupferminc, Peaceman, Wigton, Rehnberg, & Socol, 1994). 
Therefore, in a pregnancy complicated by preeclampsia, a developing fetal brain can be 
exposed to elevated cytokine levels associated with aberrant brain development and 
behavioral abnormalities in mouse models of autism and schizophrenia.   
While some studies have shown that obstetric complications are associated with a 
2.2 times increase in relative risk of schizophrenia, these studies do not address whether 
hypoxia, immunological factors, or a combination are responsible for the increased 
tendency towards developing schizophrenia (Dalman C, Allebeck P, Cullberg J, 
Grunewald C, & Köster M, 1999). Meta analysis of several studies has also found a 
significant increase in schizophrenia incidence after preeclampsia exposure, but these 
analyses have also been descriptive rather than informative of the actual cause of 
increased schizophrenia risk (Cannon, Jones, & Murray, 2002). Further study of the 
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mediators of aberrant development will be needed to understand how obstetric 
complications give rise to the pathologies of schizophrenia and autism. Moreover, a 
better understanding of the mechanisms behind altered development can leaded to future 
therapies.  
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Specific Aims and Objectives 
Previous studies have demonstrated that the in utero immune environment can 
adversely affect fetal brain development. Additionally, several studies have established 
that preeclampsia is associated with elevated pro-inflammatory cytokines in maternal 
circulation and amniotic fluid. Because of the lack of evidence for preeclampsia playing a 
causative role in the outcome of schizophrenia and autism, we seek to better characterize 
the role of immunology in these disorders.  
The specific aims of the study are: 
1. To establish that environmental factors contribute significantly to the risk 
of developing schizophrenia and autism.  
2. To review the literature investigating the relationship between pregnancies 
complicated by preeclampsia and the risk of schizophrenia and autism.  
3. To suggest further characterization of the specific events that may lead to 
abnormal brain development and mental illness after exposure to the 
immune environment caused by preeclampsia. 
4. To discuss the possible reasons for the differences in symptoms and 
pathology for ASD and schizophrenia given their similar etiologies.  
 
We hypothesize that there will be a greater incidence of schizophrenia and ASD in 
offspring of women who experienced preeclampsia and immune activation during their 
pregnancy with those offspring compared to those that do not show these markers. 
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PUBLISHED STUDIES  	  
1.	  Genes	  Vs	  Environment	  	  
	  
1.1	  Autism	  	  
Many neuropsychiatric and developmental disorders have complicated etiologies 
that are not entirely explained by genetics alone. In the cases of schizophrenia and ASD, 
twin studies have confirmed evidence from family and population studies that both 
genetic inheritance and environmental factors contribute as risk factors to some extent. 
As the scientific understanding of both of these disorders has evolved over the last 20 
years, twin studies continue to investigate and predicted heritability given new diagnostic 
parameters. Despite the fact that the rarity of these disorders renders many of these 
studies underpowered, twin studies are useful in establishing a baseline estimate of 
heritability.  
While ASD runs in families and is more prevalent in males than females (4:1), 
there is no established genetic cause for most cases of this disorder. Despite the lack of 
clearly responsible genes, early family studies reported high genetic heritability (about 
90%) for ASD. However, recruitment of subjects for these studies was not limited to 
validated cases of ASD by current standards. To replicate the environmental stressors 
associated with having a disabled sibling, contemporary studies also include control 
families in which one child has Down’s syndrome (Bolton et al., 1994; Pickles et al., 
2000). Family history from 99 autistic and 36 Down’s syndrome probands found a higher 
familial loading for autism (2.9%) compared to Down’s syndrome (0%). A larger study 
surveying 3,095 first or second-degree relatives of 185 families (149 with a child with 
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autism and 36 control families with a child with down syndrome), also confirmed an 
increased risk of autism among relatives of those with the disorder (Pickles et al., 2000). 
However, the expression patterns within these families did not reflect x-linked 
inheritance nor imprinted x-linked inheritance, suggesting ASD is a heterogeneous 
disorder caused by many factors (Pickles et al., 2000) 
Confirming a role for both environment and genetics, an early twin study reported 
a 36% concordance rate for ASD in monozygotic twins and a 0% concordance for 
dizygotic pairs (Folstein & Rutter, 1977). However, the representative group was of 
limited size with only 21 same-sexed twin pairs, 11 being monozygotic and 10 dizygotic. 
All twin pairs had one child with ASD, however recruitment of subjects did not exclude 
those exposed to biological hazards that could cause brain injury in utero. Of the 17 pairs 
discordant for autism, 12 may have been exposed to brain damage due to biological 
hazards such as a pathologically narrow umbilical cord, neonatal apnea, low birth weight, 
or encephalitis. This finding suggested that in addition to genetic risk factors, perinatal 
exposure to biological hazards predisposes a child to developing ASD. A larger, more 
recent twin study conducted in 47 monozygotic and 41 dizygotic pairs with validated 
cases of ASD found a much smaller difference in concordance between monozygotic and 
dizygotic twins, suggesting a greater role for environment in the etiology of ASD that 
previously thought (Hallmayer, 2011). Concordance in male twins with ASD was 0.58 
for 40 monozygotic pairs (95% CI, 0.42-0.74) and 0.21 for 31 dizygotic pairs (95% CI, 
0.09-0.43). Despite the higher prevalence of ASD in males, twin pairs of both sexes 
yielded consistent trends in concordance in with the concordance for females being 0.60 
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for 7 monozygotic pairs (95% CI, 0.28-0.90) and 0.27 for 10 dizygotic pairs (95% CI, 
0.09-0.69). In contrast to earlier studies, this investigation concluded that the genetic 
heritability for autism is 37% (95% CI, 8%-84%) while shared environmental factors 
contribute 55% (95% CI, 9%-81%) of liability (Hallmayer, 2011). The disparity in 
concordance between monozygotic and dizygotic twin pairs is indicative of the influence 
of prenatal factors to the risk of disease. While monozygotic concordance is higher, 
dizygotic concordance is greater than previously predicted, leaving room for in utero 
environment to impact disease risk. The incomplete concordance for monozygotic twins 
also is also evidence that environmental factors play a role.  
 
1.2	  Schizophrenia	  	  	  
Schizophrenia is a neuropsychiatric disorder with a high estimated heritability 
ranging from 83-87% (Cardno & Gottesman, 2000). Twin studies have illuminated the 
extant to which genetic contributions impact the risk of developing schizophrenia. A 
Danish based study conducted in 44 twin pairs used contemporary diagnostic criteria for 
schizophrenia to measure concordance rates in 13 monozygotic and 31 dizygotic twins. 
Using ICD-10 criteria, concordance was 44% for monozygotic pairs and 3% in dizygotic 
pairs (Klaning, 2015). Similar concordance rates have been reported for monozygotic 
pairs in previous studies using older diagnostic criteria. The criteria and populations used 
in these studies are summarized in Table 2. While there are consistent findings for the 
concordance rate in monozygotic twins, there is more variability for dizygotic twins. This 
raises many questions about the impact of shared prenatal environments on schizophrenia 
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risk. Also, two-thirds of monozygotic twins share a placenta, which is a major 
environmental factor not accounted for in these calculations for genetic heritability 
(Patterson, 2007). 
 
Table 2. Concordance Rates for Schizophrenia from Twin Studies. 
Twin studies conducted in different countries using different diagnostic criteria for schizophrenia have found 
similar concordance rates for monozygotic twins. Adjusted from Cardno et al. to include only schizophrenia.  
MZ, monozygotic; DZ, same sex dizygotic 
 
Because Schizophrenia is unlike autism, in that it is generally diagnosed in 
adulthood, the role of pre-natal environmental risks are not clearly represented by 
concordance rates in twins. Because of relatively later diagnosis, the concordance rate in 
twins is a reflection of both prenatal and postnatal factors, rather than genetic factors 
alone. While the concordance rate of less that fifty percent indicated that schizophrenia is 
not entirely due to genetic causes, whether environmental factors contribute to risk 
Authors Country Ascertainment Diagnostic 
Criteria 
N of pairs and 
concordance 
Heritability 
Estimate 
(95% CI) MZ DZ 
Klaning 
(1996)  
Denmark Population 
register 
ICD-10 13 
(44%) 
17 
(11%) 
 
Cannon et 
al. (1998)  
Finland Population 
register 
ICD-8, DSM-
III-R after 1987 
67 
(46%) 
186 
(9%) 
83% (75, 89) 
Tsujita et al. 
(1992, 
1996)  
Japan Hospital 
admissions 
DSM-III-R 18 
(50%) 
7 
(14%) 
 
Cardno et 
al. (1999)  
UK Hospital 
register 
RDC  42 
(41%) 
56 
(5%) 
82% (71, 90) 
DSM-III-R 40 
(43%) 
50 
(0%) 
84% (19, 92) 
ICD-10 43 
(42%) 
50 
(2%) 
83% (7, 91) 
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prenatally or prenatally is not clear. According to the “neurodevelopmental hypothesis” 
of schizophrenia, environmental factors harm the developing brain, manifesting as 
neuropsychiatric symptoms later in life.  
 
2.	  Preeclampsia	  and	  Prenatal	  Environmental	  Risk	  Factors	  	  
 
2.1	  Preeclampsia	  	  
During pregnancy, fetal cytotrophoblast cells acquire endothelial morphology and 
invade maternal endometrial spiral arteries at the implantation site (Pennington et al., 
2012). After enmeshing with maternal endothelial cells in the artery walls, the vessel 
becomes “leaky,” permitting maternal blood to fill the intervillous spaces of the placenta. 
In preeclampsia, there is incomplete remodeling of the spiral arteries by fetal cells and 
blood flow is impaired. Doppler ultrasound studies confirm impaired placental perfusion 
and incomplete vascular remodeling (Aquilina & Harrington, 1996). While endovascular 
remodeling occurs as 9 weeks of gestation and placental perfusion begins at 10-12 weeks, 
preeclampsia can not be diagnosed until 20 weeks (Caniggia, Winter, Lye, & Post, 2000).  
It is unclear if vascular abnormalities are a cause of preeclampsia or another symptom of 
an underlying issue that also leads to preeclampsia.  
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Figure 1. Preeclampsia as a Multifactorial Disease.  
Genetics and environment may synergistically contribute as risk factors for developing preeclampsia. 
Preexisting immune dysfunction can compound inflammation that will expose the developing fetus to cytokines 
known to alter brain development.  
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2.2	  Preeclampsia	  as	  a	  Risk	  Factor	  
	  
The relationship between obstetric complications and psychiatric disorders is a 
well-studied topic that has contributed support to the developmental model of 
schizophrenia. Some of the strongest evidence for an elevated risk of schizophrenia 
following in utero exposure to preeclampsia comes from a longitudinal study of the 
Swedish National Birth Cohort by Dalman et al (Dalman C et al., 1999). Follow-up was 
performed on 507,516 children born between 1973 and 1977 with a diagnosis of 
schizophrenia between 1987 and 1995. There were 238 cases of schizophrenia as 
measured by the IDC9 (41.6% female) and 507,278 controls. Adjustments were made for 
maternal age, year of birth, maternal history of psychosis, marital status. Preeclampsia 
was associated with a relative risk of 2.5 (95% CI 1.4-4.5) and was also the only obstetric 
complication found to have a significant increase of risk.  
While Dalman et al. used a large cohort, meta-analysis performed on several 
studies can provide a more reliable view on prenatal risk factors. Including Dalman et al, 
six studies were utilized to perform a meta-analytical review of preeclampsia as a risk 
factor for schizophrenia (Cannon et al., 2002). In total, there were 1,720 participants with 
schizophrenia, of which 75 had preeclampsia exposure, and 510,275 control subjects of 
which 18,289 has preeclampsia exposure. Preeclampsia was associated with a slightly 
elevated risk of schizophrenia (odds ratio of 1.36 and 95% CI of 0.99 to 1.85, p=0.05), 
however this risk was much lower than that previously reported by Dalman et al. With an 
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odds ratio less than two according to this meta-analysis, the risk posted by preeclampsia 
is controversial, but not without support.  
A more recent study published after this meta-analytic review also reported a 
higher relative risk for schizophrenia after preeclampsia exposure. In this Danish nested-
case control study, information was collected from the Danish Psychiatric National 
Register on 227 individuals with schizophrenia and 5,416 matched controls. Diagnoses 
for schizophrenia were made with the ICD-8 or ICD-9 guidelines. After adjusting for 
familial psychiatric history, socio-economic status and demographic factors, 
schizophrenia was associated with preeclampsia with an incidence rate ratio of 2.72 (95% 
CI 1.0-7.3). However, only five of the schizophrenic individuals had been exposed to 
preeclampsia. Like previous studies comparing the overlap of multiple rare diseases, this 
investigation also lacks sufficient breadth and sample size to be conclusive. With 
variability in the reported odds ratio for the risk of schizophrenia after preeclampsia 
exposure, more studies focusing on this issue would be valuable to establish a 
relationship between these two disorders. Also, as the last meta-analysis on schizophrenia 
and obstetric complications was published over ten years ago, a new review of 
contemporary publications, with a focus on preeclampsia, is also in need.  
The early onset of symptoms and pathology of ASD suggest that the etiology if 
this disorder is linked to neurodevelopment and events that occur in utero. The first meta-
analytic review on obstetric complications and ASD was performed by Gardener et al and 
revealed no significant increase in risk of ASD with preeclampsia exposure (effect 
estimate of 1.01 and 95% CI of 0.8-1.27) (Gardener, Spiegelman, & Buka, 2009). This 
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review utilized 25 publications on preeclampsia and ASD published prior to 2007. 
However, these studies were not screened for methodological strength, results from the 
included studies were not weighted for quality and several did not use current operational 
criteria for ASD. While broad inclusion criteria maximize the data available for analysis, 
quality control and reliability can be compromised. These shortcomings necessitated the 
subsequent meta-analytic review by Guinchat et al. on studies published after March 
2007 (Guinchat et al., 2012). Of the studies eligible for analysis, four reported significant 
results for preeclampsia as a risk factor with effect estimates between 1.49 and 1.69.  
Moreover, a very recent population-based case-control study using the Childhood Autism 
Risk from Genetics and Environment (CHARGE) cohort reported evidence of 
preeclampsia as a risk factor for ASD (Walker CK et al., 2015).  In a group of 517 
individuals with ASD and 350 typically developing controls, an elevated risk of ASD was 
found to be associated with exposure to preeclampsia (adjusted odds ratio of 2.36; 95% 
CI, 1.18- 4.68) and severe preeclampsia (adjusted odds ratio of 2.29; 95% CI, 0.97- 5.43). 
Given the trend in recent literature, an updated and rigorous meta-analytic review on 
studies employing contemporary diagnostic criteria for ASD would be valuable in 
illuminating the role of preeclampsia as a risk factor in pervasive development. While 
recent publications present strong evidence for elevated risk of ASD with preeclampsia, 
these studies fail to include measurements of clinical parameters such as cytokines or 
hormones in either the mother or fetus that can point to causation.  
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2.3	  Preeclampsia	  and	  Inflammation	  	  	  
 While preeclampsia is a multifactorial disease with multiple etiologies, there is 
some evidence to suggest that a subgroup of cases may be related to underlying maternal 
immune irregularities(Duckitt & Harrington, 2005). In a systematic review of controlled 
studies, Dukket and Harrington reported that preexisting autoimmune disorders are a risk 
factor for preeclampsia (relative risk 6.9, 1.1 to 42.3). Two cohort studies in this review 
also reported a greater relative risk for developing preeclampsia in women who have 
antiphospholipid antibodies such as anticardiolipin antibody or lupus anticoagulant. In 
addition to autoimmune induced inflammation, irregularities in anti-inflammatory 
mechanisms are also associated with preeclampsia. IL-10 is an anti-inflammatory 
cytokine that contributes to fetal allograft tolerance (Makris, Xu, Yu, Thornton, & 
Hennessy, 2006). Significant reduction in placental mRNA expression of IL-10 was 
reported in women with preeclampsia compared to controls (p=0.015, n=43) (Makris et 
al., 2006). This difference in placental mRNA expression was associated with an Il-10 
promoter polymorphism.  
 Further evidence for an immune component to preeclampsia has come from 
studies on monocytes, the immune cells responsible for triggering inflammation. A recent 
study found that monocytes isolated from women with preeclampsia (n=85) express more 
pro-inflammatory markers (M1 activation) than those of normotensive women 
(n=52)(Medeiros et al., 2014). The presence of more M1 activated monocytes causes 
systemic inflammation, either as a symptom of preeclampsia, or as a cause of it. The 
same study confirmed lower synthesis of anti-inflammatory IL-10 by monocytes from 
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preeclamptic women in vitro. M1 polarization of macrophages and lower IL-10 
production was consistent in both early- and late- onset preeclampsia.  
 Without the presence of an underlying immune disorder, the pathogenesis of 
preeclampsia may itself cause secondary inflammation. Regardless of the precipitating 
event, high blood pressure and irregular cytotrophoblast invasion of placental arteries 
results in vascular damage (Pennington et al., 2012). Trophoblastic cell death in the 
placenta may release paternal antigens and induce the maternal immune system to 
respond with inflammation (Johansen, Redman, Wilkins, & Sargent, 1999). There are 
more trophoblastic cells and cell fragments in the uterine vein blood, but not in peripheral 
blood, of women with preeclampsia compared to controls (p<0.05, n=38). Another 
possible result of incomplete remodeling of spiral arteries is vascular instability and 
hypoxia-reperfusion injury. As blood flows through these high resistance vessels, the lack 
of trophoblastic invasion renders the vessels non-vasoactive, causing intermittent hypoxia 
followed by normoxia. Hypoxia-reperfusion injury is associated with an increase in pro-
inflammatory TNF-α production by the placenta(Hung, Skepper, & Burton, 2001).  
There is abundant literature comparing cytokine levels in preeclamptic and 
normotensive women. A selection of case-control studies measuring cytokine levels is 
summarized in Table 3. Both placental and plasma inflammatory cytokines have been 
shown to be elevated in pregnancies complicated by preeclampsia by different studies.  
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Table 3. Selected studies Investigating Inflammation in Preeclampsia  
*PE, preeclampsia 
  
The abundance of literature on this topic precludes variability in study design and 
quality with some studies failing to use proper control parameters (Wang & Walsh, 1996) 
and others being underpowered (Benyo, Smarason, Redman, Sims, & Conrad, 2001). A 
systematic meta-analysis by Lau et al. is therefore useful in determining consensus and 
discordance in the literature (Lau et al., 2013). Unlike previous reports, this study 
includes separate analysis on severe vs. mild preeclampsia as well as early vs. late onset 
of the disease. Studies were also subcategorized by trimester to provide data beyond only 
the third trimester. Moreover, cytokine levels in human plasma are physiologically 
unlikely to be at or near zero, making their distribution non-normal. In contrast to 
Study Parameters Control Findings 
Kupferminc 
et al (1994)  
Severe preeclampsia 
n=21, pregnant control 
n=26 
 parity, 
gestational age; 
uneventful term 
pregnancies  
Increased plasma and 
amniotic TNF-α in patients 
with PE* 
Wang and 
Walsh 
(1996)  
Pre-eclampsia  n=11; 
pregnant control n=15 
 
_ 
 
Increased placental TNF-α 
protein concentration and 
mRNA in patients with PE 
Vince et al 
(1995)  
Pre-eclampsia n=31; 
pregnant control n=31 
Age, parity, 
gestational age 
Increased IL-6, TNF-α, and 
soluble TNF-R in patients 
with PE 
Benyo et al 
(2001)  
Preeclampsia n=8, 
control pregnant women 
n=8 
Cesarean 
section 
Increased circulating TNF-α, 
but no change in placental 
cytokine levels in patients 
with PE 
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previous meta-analyses, this study employs non-parametric statistics to account for non-
normally distributed cytokine levels in the population.  
Surveying twenty-three studies with a total of 1,015 women with preeclampsia dn 
925 normotensive women, Lau et al. found that circulating TNF-α is higher in 
preeclamptic women. The mean difference in TNF-α levels was 8.11 pg/ mL (95% CI 
5.87-10.34 pg/mL).  In thirteen studies comprising 425 preeclamptic women and 363 
normotensive pregnant women, maternal circulating IL-6 was found to be significantly 
higher in women with preeclampsia. The mean difference was 7.96 pg/mL (95% CI 2.65-
13.28 pg/mL). After analyzing data according to trimester, it was found that in the third 
trimester, preeclamptic women had higher TNF-α and IL-6 compared to controls. There 
was, however, insufficient evidence to confirm these phenomena in first and second 
trimester pregnancies. There was insufficient data to perform analysis based on early or 
late onset preeclampsia. 
Figure 2. Meta-analysis of Il-6 Levels in Women with Preeclampsia. Taken from Lau et 
al.  
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While studies previously reviewed in this paper have reported lower expression of 
the anti-inflammatory cytokine IL-10 in women with preeclampsia(Makris et al., 2006; 
Medeiros et al., 2014), the results of meta-analysis by Lau et al found elevated IL-10 in 
preeclamptic women(Lau et al., 2013). The meta-analysis, however, was performed using 
only papers reporting elevated IL-10 rather than using a weighted average of studies with 
different outcomes. Given the consistency of findings on elevated pro-inflammatory 
cytokines in women with preeclampsia, lower Il-10 expression would be more consistent 
with the immune state described by other findings. Further in-depth study on this issue 
and a more comprehensive meta-analysis is required to better understand the role of Il-10 
in the preeclamptic immune environment.  
  
2.4	  Neuroinflammation	  in	  Neurodevelopmental	  Disorders	  
 
 The effect of neuroinflammation on neurdevelopment has long been studied in the 
context of infectious disease. The Prenatal Determinant of Schizophrenia (PDS) was a 
prospective study based on a cohort of 20,000 pregnant women in Northern California, 
from which samples of sera were collected during prenatal visits (Opler & Susser, 2005).  
This study was unique in that prenatal infection was confirmed with serological measures 
of anti-influenza antibodies. A seven-fold increase in the risk of schizophrenia and 
schizophrenia spectrum disorders (SSD) was found in individuals with influenza 
exposure during the first trimester. However, developmental abnormalities are associated 
with various prenatal infections, rather than one specific pathogen.  Rubella, toxoplasma 
gondii, measles, polio, herpes simples, and genital infections during pregnancy have also 
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been associated with increased risk of developmental disorders in offspring (Meyer, 
Feldon, & Yee, 2009). This suggests that the immune response, which is common to all 
of these infections, may be the mediator of developmental changes, rather than the 
infectious agents, themselves. The pro-inflammatory cytokines induced by such 
infections may alter brain development leading to schizophrenia and autism.  
 This hypothesis is supported by studies performed on mouse models of autism 
and schizophrenia. The core symptoms of autism such as repetitive behavior and reduced 
social behavior have been produced in mice using the maternal immune activation (MIA) 
model of autism. In this model, injecting pregnant mice with an immunogenic compound 
such as virus, bacterial lipopolysaccharide (LPS), or double-stranded RNA (poly (I:C)). 
Offspring born to pregnant mothers inject with poly (I:C)) showed behavioral 
abnormalities. Mice emit USVs as pups to communicate with their mothers and as adults 
in response to mates or other mice. MIA offspring made fewer ultrasonic vocalizations 
(USVs) during both childhood and adulthood. These USVs were also harmonically and 
qualitatively different from those of control mice. Marble burring is a test of repetitive 
behavior in which mice are observed burring a field of marbles into cage bedding. MIA 
offspring also displayed increased marble burring behavior, consistent with autistic trains 
in humans. Self-grooming is also used as an index of repetitive behavior and was 
observed to be increased in MIA offspring.  
The MIA model is also relevant to schizophrenia. Using the MIA model, Shi et al. 
infected pregnant mice at day 9.5 (mid-pregnancy) with influenza virus and measured 
behavioral abnormalities in the offspring (Shi, Fatemi, Sidwell, & Patterson, 2003). Mice 
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with prenatal influenza exposure displayed abnormal behaviors consistent with mouse 
models of autism and schizophrenia such as deficiencies in prepusle inhibition (PPI), 
social interactions, and exploratory behavior in open field and novel-object tests. The 
abnormal behavior was ascribed to the immune reaction to the virus as influenza does not 
spread beyond the lung and no viral particles were found in histological preparations of 
mouse brains. Furthermore, PPI deficits remained when maternal injections were made 
with only synthetic Poly (1:C) rather than live virus. The immune system recognizes and 
responds to poly (I:C) even in the absence of a live virus and a deficit in PPI in the 
acoustic startle response is one of the hallmarks of schizophrenia in mouse models of the 
disease.  
The immune reaction and subsequent developmental changes in response to poly 
(I:C) are mainly mediated by the inflammatory cytokine IL-6 (Smith, Li, Garbett, 
Mirnics, & Patterson, 2007). In fact, co-injection of poly (I:C)  and anti IL-6 antibody 
prevents 92% of changes in gene expression in the brains of offspring exposed to the 
challenge. Additionally, IL-6 KO mice injected with poly (I:C) show no behavioral 
deficits after pre-natal antigen exposure. While these studies were conducted in a mouse 
model, human studies have also suggested a relationship between elevated immune 
response and schizophrenia.  
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Table 4. The Relationship Between Prenatal Immune Challenge and Mental Illness.  
Schizophrenia and related disorders, such as Somatic Symptom Disorder, are associated with exposure to 
immune activation in utero. Adjusted from Khandaker et al (2013)(G. M. Khandaker, Zimbron, Lewis, & Jones, 
2013)  
 
Study 
Case/ 
control 
Case 
Definition Exposure Adjustment/ control  Main Finding 
Buka et 
al., 2001 27/54 
affective 
and non 
affective 
psychosis 
by DSM IV 
Il-1b, Il2, 
Il4, Il8, 
TNF-α 
gender, ethnicity, 
social class, maternal 
mental illness, weight 
gain and smoking 
during pregnancy  
increased TNF-α in case 
mothers; OR for psychosis 
8.5 (p<0.03) in offspring 
of women with both third 
trimester infection and 
TNF-a levels >75th.  
Brown et 
al. 2004  59/118 
SSD by 
DSM-IV 
IL-1β, IL-
6, IL-
8, TNF-α 
Fetal age, gender, 
maternal age, social cl
ass, ethnicity 
Nearly two fold increase 
in mean and median Il-8 
at second/third trimester 
in case mothers  
Brown et 
al. 2000  58/778 
SSD by 
DSM-IV 
Respiratory 
infection 
Maternal ethnicity, 
education and smoking 
during pregnancy  
OR SSD 2.13  (95% CI 
1.05–4.35),  
schizophrenia 2.07 (95% 
CI 0.8–5.36) 
Babulas 
et al. 
2006 71/772 
SSD by 
DSM-IV 
Genital/repr
oductive 
infection 
Maternal age, 
ethnicity, education 
and mental illness  
OR SSD 5.03 (95% CI 
2.00–12.64) 
 
Moreover, the immunological events followed by maternal infections are not 
confined to the mother. Evidence from both human and mouse studies suggest that 
cytokines cross the placenta and enter fetal circulation where they can also cross the 
blood brain barrier. After performing peritoneal injections of LPS on pregnant mice, 
Gayle et al found elevated inflammatory cytokines in both the maternal blood and fetal 
amniotic fluid(Gayle et al., 2004). Previous studies using higher doses of LPS have 
reported elevated fetal brain cytokine production (Cai, Pan, Pang, Evans, & Rhodes, 
2000; Urakubo, Jarskog, Lieberman, & Gilmore, 2001). While fetal brain cytokine 
mRNA levels did not change in this study, elevated stress markers were found such as 
corticotropin releasing hormone. Because mRNA levels reflect only production of the 
cytokines by the brain, and not exposure to them from circulating levels, it is possible 
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that cytokines reach the brain by crossing the blood brain barrier (BBB).  Il-1β, TNF-α, 
and Il-6 cross a normal human adult and murine BBB(Dammann & Leviton, 1997). The 
BBB is also thought to be more permeable in the fetus compared to adults(Dammann & 
Leviton, 1997).  Additionally, pro-inflammatory cytokines, themselves increase BBB 
permeability, leading to even greater likelihood that these compounds reach and alter the 
developing brain. 
 
3. Neuroimmunology and Development:	  Mechanisms 
How cytokines impart the developmental changes or brain damage associated 
with psychiatric disorders is still not well understood. Several different roles have been 
found for cytokines in neural plasticity and differentiation. Glia are responsible for 
various aspects of brain development from neuronal migration to modulation of precursor 
cell growth and differentiation (Stolp, 2013). Microglia are the resident macrophages of 
the CNS, become active in response to circulating inflammatory cytokines, and are 
responsible for immune functions such as phagocytosis and additional cytokine 
production. Cytokines produced by microglia modulate differentiation of neural 
progenitor cells. Using neutralizing antibodies and recombinant cytokines, Nakashini et 
al. showed that Il-6 is essential for the induction of astrocyte differentiation and can 
accordingly shift the glial population when elevated (Nakanishi et al., 2007). TNF-α  also 
induced astrocyte differentiation(Whitney, Eidem, Peng, Huang, & Zheng, 2009). 
Astrocytes are responsible for neuronal differentiation, causing two-fold increase in 
neural stem proliferation and tenfold rate of differentiation in co-cultures (Whitney et al., 
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2009).  Altering temporal regulation of astrocyte production due to acute inflammation 
may disrupt normal brain development.  
Both Il-6 and TNF-α have also been shown to inhibit neuronal differentiation in 
the hippocampus (Liu, Lin, & Tzeng, 2005; Vallières, Campbell, Gage, & Sawchenko, 
2002). Il-6 produced by microglia decreases neuronal differentiation by 50% in cell 
culture models, and this effect is loss with treatment of anti Il-6 antibody (Whitney et al., 
2009). The effect of TNF-α on neuronal differentiation and survival is less clear. 
Activated microglia expressing TNF-α prevented neuronal differentiation in cell culture 
studies. Furthermore, blocking TNF-α action with soluble receptors or the inhibitor 
pentoxyfylline was somewhat effective in rescuing neuronal differentiation. However, 
other studies report no initial loss of neural differentiation with TNF-α treatment. These 
differences in experimental outcomes may be accounted for by differences in techniques 
and the models being used. The length of exposure to TNF-α as well as differential 
expression of receptor subtypes may also be relevant.  
Overexpression of microglial Il-1β and Il-6 due to inflammation exposure in utero 
has also been associated with altered glutaminergic synapses in adult mice (Roumier et 
al., 2008). Furthermore, TNF-α increases synaptic activity in rat hippocampal slices in 
vitro, which can lead to altered brain development and behavior(Grassi et al., 1994). In a 
rat study, a synthetic, highly active fusion protein of Il-6 increased neurotrophins (NT) of 
the nerve growth factors (NGF) family (März, Heese, Dimitriades-Schmutz, Rose-John, 
& Otten, 1999). NGFs influence synaptic strength, which can lead to altered cognition 
(Nawa, Takahashi, & Patterson, 2000). These neuroprotective NGFs were induced 
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differentially throughout the brain and had the greatest effect in the hippocampus, cortex 
and cerebellum(März et al., 1999).  
  Brain derived neurotropic factor (BDNF) is the main regulator of neuronal 
survival, differentiation and synapse maturation(Heese, Hock, & Otten, 1998). 
Inflammatory cytokines such as Il-1 and NGF suppress BDNF expression while Il-6 
enhances its expression(Nawa et al., 2000). Differential modulation of BDNF in various 
brain regions by multiple cytokines can have global effects on cognition and 
development. The molecules regulated by BDNF are also altered in schizophrenia. 
Examples of this include somatostatin, calbindin D, TH/ Dopamine, synaptophysin, and 
CCK, among others(Nawa et al., 2000). Somatostatin induces the inhibitory action of the 
dorsolateral prefrontal cortex, which is abnormally active in schizophrenia(Morris, 
Hashimoto, & Lewis, 2008). Reduced calbindin-positive interneurons have been reported 
in schizophrenia. Reducing calbindin in inhibitory interneurons reduced their excitability, 
leading to increased down stream disinhibition and altered cognition(Chance, Walker, & 
Crow, 2005).  
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DISCUSSION 
 
 While there is evidence supporting a developmental and immunological model for 
schizophrenia and autism, there is a lack of literature characterizing the circumstances 
that lead to the unique pathologies of these different diseases. The most obvious 
explanation for the differences in these diseases is that the timing of an abnormal 
inflammatory event can interfere with different developmental stages of the brain, thus 
manifesting as different symptoms. For instance, autism is more associated with 
cerebellar pathology than is schizophrenia. The cerebellum reaches full development 
relatively late in fetal life, therefore either acute inflammation in the third trimester, or 
chronic inflammation persistent throughout development would be able to impart 
cerebellar pathologies(Meyer et al., 2011). Further study of the temporal influence of 
inflammatory events on development and psychiatric manifestations is needed.  
 Alternatively, the shared aspects of schizophrenia and autism such as social 
deficits and altered sensory processing, may be explained by neuroinflammation in early 
development which may either persist leading to one disease or resolve leading to the 
other disease. The outcome and course of neuroinflammation may be determined by 
either additional environmental factors such as access to healthcare or other obstetric 
complications, or by genetic susceptibility to immune disorders. Failing to responding to 
an acute inflammatory event with sufficient anti-inflammatory measures may be a result 
of genetic background (Figure 3). Genes contributing to the risk of preeclampsia may 
also modulate the severity of the inflammatory exposure in utero. The difficulty in tracing 
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these subtle contributing factors in is the lack of a sufficient study size to be able to 
capture rare genetic susceptibilities or alternative environmental factors.  
 
Figure 3. Immune profiles in Schizophrenia and Autism.  
Taken from Meyer et al 2011(Meyer et al., 2011) Like maternal infection, preeclampsia initiates acute 
inflammation in the fetal environment. The persistence or suppression of inflammation may rely on genetic 
factors, which differentiate the outcomes of schizophrenia and autism by modulating latent versus chronic 
neuroinflammation. The acute inflammatory event, however, is present in both cases and may account for 
shared attributes between both disorders.  
 	  
 In their review of the neuroimmunology of developmental disorders, Meyer et al.  
put forth a hypothesis that the pathologies of schizophrenia and autism are shaped by 
latent inflammation and chronic inflammation, respectively, and that the course of either 
immunological profile is determined by differences in genetics (Meyer et al., 2011).  
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There is evidence that prenatal immune challenge can lead to permeanent alterations in 
cytokine production and immune reactivity. Offspring of pregnant mice injected with 
poly (I:C) have elevated brain cytokine levels from birth to adulthood (Garay, Hsiao, 
Patterson, & McAllister, 2013). Moreover, these elevations are region-specific and 
coincide with areas known to be abnormal in schizophrenia and autism. While both IL-1β 
and IL-10 (Il-6 is elevated, but p=0.09) are elevated at birth, Il-6 and IL-10 are elevated 
during adulthood in the frontal cortex. In the hippocampus, Il-6 is elevated at birth, and 
there are persistent differences in other cytokine levels throughout development.  
 A theory of chronic inflammation in autism is supported by evidence from human 
studies.  A small clinical study (n=10) reported significantly higher levels of TNF-α in 
the CSF of children with autism (Chez, Dowling, Patel, Khanna, & Kominsky, 2007). In 
support of these findings, another study using immunohistochemical techniques reported 
elevated glial activation in brain tissue from human subjects with autism(Vargas, 
Nascimbene, Krishnan, Zimmerman, & Pardo, 2005). The cerebellum, which is abnormal 
in autistic patients, was most notably affected by elevated inflammation. Lastly, in a case-
control study, peripheral blood monocytes isolated from autistic children were found to 
produce higher levels of proinflammatory cytokines and lower anti-inflammatory IL-10 
in response to synthetic immune stimulants (Molloy et al., 2006).  
 Conversely, schizophrenia is associated with higher levels of both pro- and anti-
inflammatory cytokine consistent with the pathology of the latent-inflammation model. In 
a systematic and quantitative review of 62 studies with a total of 2,289 schizophrenic and 
1,858 control individuals, Potvin et al. found that pro-inflammatory cytokines, including 
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IL-6, are significantly elevated in patients with schizophrenia. On the other hand, serum 
levels of IL-10 were found to be elevated in a subset of schizophrenics resistant to certain 
treatments (Maes et al., 2002). Other markers of elevated anti-inflammatory mediators 
have also been found in individuals with schizophrenia including the IL-1 receptor 
antagonist, TGF- β, and soluble TNF receptor (Meyer et al., 2011). This unique immune 
environment may act as a switch for the schizophrenic phenotype during development, 
allowing for dampened inflammation after an initial damaging acute event. 
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CONCLUSION 
Schizophrenia and autism are disorders linked to disturbances in development. 
While both disorders are associated with genetic risk factors, incomplete concordance in 
twins suggests environmental factors are important for the development of both diseases. 
One well studied environmental risk factor for both schizophrenia and autism is obstetric 
complications. Specifically, maternal infections during pregnancy have been studied for 
their potential to expose a fetus to inflammatory cytokines known to modulate brain 
development. Preeclampsia is another obstetric complication associated with a greater 
risk of schizophrenia and autism in offspring. Preeclampsia ignites an immune response 
similar to that seen during prenatal infections and can therefore mediate 
neurodevelopmental changes in the same way previously studied maternal infections can.  
 Possible preventative therapies have been proposed, however none are in 
use, nor have they been tested in pregnant human populations for the purpose of 
preventing abnormalities in a developing fetus. Previously described experiments in mice 
have demonstrated that behavioral abnormalities that arrive from prenatal IL-6 exposure 
are ameliorated by concurrent IL-6 antibody administration (Smith et al., 2007). Because 
cytokines are required in normal brain development, finding appropriate situations for 
this therapy and proper dosage would be greatly challenging. Interferons (IFNs) are 
immune mediators expressed by astrocytes in response to viral challenge. Interferon-
induced transmembrane-3 (IFITM3) is a necessary component of the IFN pathway and 
has been shown to be elevated in brains of experimental mouse models of schizophrenia 
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and autism (Ibi & Yamada, 2015). Mice without IFITM3 expression are spared the 
alterations in neuronal and dendritic maturation seen in wild type mice after pre-natal 
immune challenge. Therapeutics targeting IFITM3 also have the potential to prevent 
brain damage, however the role of IFNs in normal brain development is not well 
understood. Therapies focusing on immune modulation share the common risk of 
disrupting normal functions of the immune system in development. Therefore, more 
research on the normal levels and functions of cytokines and other immune mediators in 
development will be needed before viable therapeutic can be developed in this class. 
Furthermore, determining threshold for what cytokines levels are normal or abnormal 
will be necessary to determine when treatment with immune suppressors is appropriate. 
Lastly, drug delivery will be sensitive to differences in drug availability for the other and 
fetus. 
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